Shares in Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) climbed 7 per cent to 0.15p this week. The gain followed news that the firm had cleared an early hurdle in a United States government programme. That programme tests new treatments for cocaine and methamphetamine dependence.

The National Institute on Drug Abuse is part of the US government’s medical research network. It has agreed to advance Solvonis’s experimental compound, SVN 015, into a further round of studies. As a result, a possible stimulant addiction treatment now sits a step closer to reality. It arrives in a field where medicine has offered very few answers so far.

That gap matters a great deal. No medicine is currently approved by the US Food and Drug Administration for stimulant use disorder. Behavioural therapy remains the only established option for people trying to break away from cocaine or methamphetamine use. Any credible treatment for stimulant use disorder would therefore mark a significant shift. It is a condition that has proven hard to address with medication alone.

First Hurdle Cleared

The National Institute on Drug Abuse runs and funds this work itself, through its Addiction Treatment Discovery Program. This gives Solvonis access to specialist laboratories, without the company having to pay for them or issue new shares. Meanwhile, Solvonis keeps full ownership of the compound and its patents throughout the process.

The initial screening examined whether SVN 015 might interfere with the heart’s electrical activity. That kind of problem has ended the development of similar drugs before now. Solvonis said the compound performed better on these measures than GBR 12909. That compound was tested by the agency decades ago as a possible treatment for cocaine dependence. It is known to affect several cardiac ion channels. Ion channels are protein gateways that control the flow of charged particles in and out of heart cells, and they govern the organ’s rhythm. A cleaner cardiac profile matters for any future stimulant addiction treatment, since heart safety concerns have ended similar programmes early in the past.

Still, the company was careful to note that these are laboratory results only. They do not establish that the drug is safe in animals or humans.

How SVN 015 Works

SVN 015 targets the transporters that recycle dopamine and serotonin. These are two chemical messengers in the brain that stimulants such as cocaine hijack. By focusing on this system, researchers hope to find a stimulant addiction treatment that addresses the underlying biology of dependence. That would be a shift from simply managing its symptoms.

Next Steps For Solvonis

The next stage of testing will include a mouse study. It will measure how quickly the compound takes effect and how long its activity lasts. Researchers will also run confirmatory tests on its binding to the dopamine transporter. Then they will follow up on its activity at a receptor linked to heart valve damage in some older drugs.

Anthony Tennyson, chief executive of Solvonis, said the agency’s decision offered external validation for further evaluation of the compound. Professor David Nutt is the company’s chief scientific officer, and a well known figure in British drugs research. He described the early findings as highly promising.

Still Years From Patients

Despite the encouraging signals, SVN 015 remains firmly at the discovery stage. Solvonis has said the compound is several years away from any human trial. It emerged from the company’s artificial intelligence assisted drug discovery work. That work is part of a broader push to find faster routes to a viable treatment for stimulant use disorder.

For now, the announcement offers a modest but genuine sign of progress. Families affected by stimulant dependence have waited a long time for new options. Whether SVN 015 ultimately reaches patients will depend on years of further testing. Still, the agency’s decision to fund the next phase marks a meaningful step. It moves the field closer to a future stimulant addiction treatment that does not yet exist.

Source: dbrecoveryresources